Latest | Instant news on finance, ETFs, IPOs etc. _第113页

09:12

【Eastroc Beverage (09980.HK): Subsidiaries Subscribe for RMB 550 Million Wealth Management Products from Huaxia Bank; Combined with Previous Subscriptions Constitutes Notifiable Transaction】NewTimeSpace News: Eastroc Beverage announces subsidiaries subscribed for RMB 550 million wealth management products from Huaxia Bank with expected yields of 2.12%-2.15%; combined with previous RMB 1,857 million subscriptions, the total constitutes a notifiable transaction under Chapter 14; funded by idle capital without affecting working capital.

Tag： Eastroc Beverage 09980.HK

08:17

【Nanjing Leads Biolabs-B (09887.HK): LBL-024 (WeilixinTM) Phase II Study for First-Line HCC Treatment Enters Expansion Stage】NewTimeSpace News: Nanjing Leads Biolabs announces WeilixinTM Phase II study for first-line HCC enters expansion stage; preliminary data shows positive efficacy and good safety in combination with bevacizumab; the drug has initiated 13 solid tumor indications in China and is the world's first 4-1BB-targeting molecule in pivotal registration trials.

Tag： LEADS BIOLABS-B 09887.HK

08:08

【China Chunlai Education Group (01969.HK): Proposes USD127.5 Million Acquisition of Dublin Business School; Expands into Irish Higher Education】NewTimeSpace News: China Chunlai Education proposes acquiring Dublin Business School for USD 127.5 million; target serves approximately 9,000 students annually with 2025 revenue of EUR 49.8 million; Irish authorities confirmed no review required; major transaction subject to shareholder approval via written consent.

Tag： CHINA CHUNLAI 01969.HK

07:56

【Wai Chun Bio-Technology (00660.HK): Appointed Exclusive Overseas General Agent for China's Leading Crane Manufacturer; Three-Year Agreement】NewTimeSpace News: Wai Chun Bio-Technology signs exclusive overseas general agency agreement with Henan Mine Crane for global markets excluding mainland China; three-year term with renewal rights; licensor is a leading Chinese crane manufacturer with annual revenue of approximately RMB 6.5 billion; company adopts a light-asset model with autonomous pricing to capture global infrastructure demand.

Tag： WAI CHUN BIOTEC 00660.HK

07:32

【BEONE MEDICINES(06160.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 464.36 million, YoY increase of 385.79%】August 05, 2026, BEONE MEDICINES(06160.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 3.22 billion, increased by 32.31% YoY

Tag： BEONE MEDICINES 06160.HK

07:32

【CHINAHEALTHWISE (00348.HK) plans to issue in total 154.09 million shares】CHINAHEALTHWISE (00348.HK) plans to issue in total 154.09 million shares.

Tag： CHINAHEALTHWISE 00348.HK

21:52

【AOM INT'L(00381.HK): Termination of Strategic Cooperation Agreement With Yalu Cloud】NewTimeSpace News: AOM INT'L(00381.HK) announced that due to failure to reach further consensus on key terms, the Company and Yalu Cloud have agreed to terminate the previously‑signed strategic cooperation agreement on 5 August 2026. No binding formal agreement has been concluded. The Board holds the view that the termination will not result in any material adverse impact on the Group’s current operations and financial position.

Tag： AOM INT 00381.HK terminate cooperation

21:48

【LYGEND RESOURCE(02245.HK): Phase‑II KPS Project of RKEF Facility Reaches Full Production, Annual Capacity Hits 185,000 Metal Tons of Ferronickel】NewTimeSpace News: Lygend Resource (02245.HK) announced on 5 August that the Phase‑II KPS Project (12 production lines, annual capacity of 185,000 metal tons of ferronickel) of the RKEF facility on Indonesia’s Obi Island has achieved full production. The Obi project now delivers a combined annual capacity of 400,000 metal tons of nickel. The Company expects to unlock scale benefits and improve profitability.

Tag： LYGEND RESOURCE 02245.HK Project Updates

21:40

【BOAN BIOTECH(06955.HK): Aflibercept Intravitreal Injection Submitted for Marketing Approval in Brazil for Wet AMD and Diabetic Macular Edema】NewTimeSpace News: Boan Biotech (06955.HK) announced on 5 August that the marketing authorization application for aflibercept biosimilar BA9101 has been filed in Brazil for wet AMD and diabetic macular edema. EYLEA recorded global sales of USD5.321 billion in 2025 and Brazil’s pharmaceutical market reached USD39 billion. Having obtained approval in China, the product is accelerating its overseas expansion.

Tag： BOAN BIOTECH 06955.HK New Drug Marketing Application

21:35

【LUYE PHARMA(02186.HK): Innovative Drug LY03015 Completes Bridging Clinical Trial in the US, Pivoting to Efficacy‑focused Clinical Study】NewTimeSpace News: Luye Pharma (02186.HK) announced that self‑developed new molecular entity LY03015, the world’s first VMAT2 inhibitor and Sigma‑1R agonist, has successfully completed a bridging clinical trial in the United States, supporting the upcoming efficacy‑oriented clinical trial in the US. Previous Phase II clinical data from China showed that the AIMS response rate reached 76.5% in the 20mg dose group, exceeding historical therapeutic benchmarks.

Tag： LUYE PHARMA 02186.HK Clinical Trial

21:23

【Shanghai-Hong Kong Stock Connect Southbound Adjustments: MINIMAX-W, LUXSHARE-ICT, CCTC Added】NewTimeSpace News: The Shanghai Stock Exchange announced adjustments to the list of eligible Southbound stocks under the Shanghai-Hong Kong Stock Connect pursuant to the SSE's implementation rules. MINIMAX-W, LUXSHARE-ICT, and CCTC have been added, effective from the next Southbound trading day. All three are industry leaders in their respective segments, spanning general artificial intelligence, precision intelligent manufacturing, and advanced materials.

Tag： MINIMAX-W LUXSHARE ICT CCTC

20:01

【VICO INTL HLDGS(01621.HK): Independent Non‑executive Director Wu Yingsi Resigns; Multiple Listing Rules Requirements Not Met】NewTimeSpace News:VICO INTL HLDGS(01621.HK) announced that Ms. Wu Yingsi has resigned as Independent Non‑executive Director and member of the Audit Committee, Remuneration Committee and Nomination Committee with effect from 5 August 2026 due to personal matters and work arrangements. Following her resignation, the Company fails to comply with several Listing Rules requirements concerning the minimum number of Independent Non‑executive Directors (at least three), minimum size of the Audit Committee (at least three), composition of the Remuneration Committee and gender diversity of the Nomination Committee.

Tag： VICO INTL HLDGS 01621.HK resignation

19:50

【EVEREST GOLD(01815.HK): Initial Exploration Progress Achieved at Shannan Mine and Shigatse Mine; Gold Mineralised Zone Delineated in Gudui Area】NewTimeSpace News: Everest Gold (01815.HK) announced the latest exploration progress at Shannan Mine and Shigatse Mine. A roughly east‑west trending mineralised zone has been preliminarily delineated in the Gudui Area of Shannan Mine, with a strike length of around 1,000 metres and a down‑dip extent of approximately 500 metres. Preliminary assay of grab samples indicates gold mineralisation, with associated antimony and cobalt mineralisation encountered in some sections. Skarn‑type polymetallic mineralisation and molybdenum mineralisation outcrops have been identified in the Xiaqiu Area of Shigatse Mine.

Tag： EVEREST GOLD 01815.HK exploration progress

19:43

【REALORD TECH(01196.HK): Approximately 9.22 Million Shares of Controlling Shareholder Meilin Holdings Sold via Forced Sale During Black‑out Period】NewTimeSpace News: Realord Tech (01196.HK) announced that 9,218,000 shares beneficially owned by Meilin Holdings, held by executive director Dr. Lin Xiaohui and Ms. Su Jiaohua, were sold on the market on 30 July 2026 through forced sale. The shares account for approximately 0.64% of issued shares. The sale took place within the black‑out period prior to the release of interim results. Nonetheless, the Directors hold the view that the sale falls within the definition of special circumstances under the Listing Rules.

Tag： REALORD TECH 01196.HK forced sale lock-up period

19:37

【REMEGEN(09995.HK): Expected H1 Revenue of Approximately RMB5.85 Billion, YoY Growth of 433%; Return to Profitability】NewTimeSpace News: Remegen (09995.HK) released its interim performance forecast. The Company expects operating revenue of approximately RMB5.85 billion for H1 2026, representing a YoY increase of 433%. Net profit attributable to owners of the parent is projected at about RMB4.7 billion, marking a return to profitability (compared with a loss of approximately RMB450 million in the same period last year). Domestic sales of core products telitacicept and disitamab vedotin kept growing, coupled with a substantial rise in technology licensing income generated from the exclusive licensing agreement for RC148 with AbbVie.

Tag： REMEGEN 09995.HK Return to Profitability

18:37

【GREENHEART GP(00094.HK): Subsidiary’s HK$400‑Million Facility Matures Unrepaid; Lender to Pursue Recovery Actions】NewTimeSpace News: Greenheart GP (00094.HK) announced that the revolving facility of up to HK$400 million provided by wholly‑owned subsidiary Silver Mount to non‑wholly‑owned subsidiary Lvsen Resources matured on 4 August 2026 and remains unpaid. The outstanding principal balance stands at approximately HK$396.4 million, with accrued interest of around HK$170.9 million. Silver Mount will take all feasible recovery actions.

Tag： Greenheart GP 00094.HK Financing Default

18:15

【C TRANSMISSION(00658.HK): New Investigative Firm Appointed for Further Investigation and Comprehensive Internal Control Review】NewTimeSpace News: C Transmission (00658.HK) announced on 6 August that Grant Thornton has been appointed to conduct further investigation, which is expected to take 5‑6 months. A comprehensive internal control review covering 13 categories will also be launched. Four recommendations raised in the prior internal control review are being implemented. The Company stated that it will treat past non‑compliant incidents with the utmost seriousness.

Tag： C TRANSMISSION 00658.HK internal control review

18:05

【HK Stock Connect Daily: CPO Concept Erupts; HAIZHI TECH GP Surges 42.9% -20260805】On August 5, the three major Hong Kong indices climbed amid volatility; the Hang Seng Index rose 0.24% to 25,915.82, the Hang Seng TECH Index rose 0.97%, and turnover was HKD 278 billion. The CPO concept erupted, with VGT up 16.18% and KB LAMINATES up 10.28%; gold stocks rose broadly, with CHINAGOLDINTL up 13.11% and the international gold price reclaiming USD 4,100; the UHV concept strengthened, with HARBIN ELECTRIC up 7.55%. Oil stocks weakened on crude prices, and optical communication stocks pulled back on U.S. ban rumors. Southbound funds recorded a net outflow of HKD 1.398 billion. HAIZHI TECH GP surged 42.9%; Goldman Sachs raised large-model revenue forecasts; HKEX's phase-II tick-size reduction took effect.

Tag： HK Stock Connect Daily HAIZHI TECH GP KB LAMINATES ChinaAMC CSI HK Equities Information Technology Integration ETF Fullgoal CSI HK Equities Internet ETF

17:55

【U-PRESID CHINA(00220.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.4 billion, YoY increase of 8.99%】NewTimeSpace News: August 05, 2026, U-PRESID CHINA(00220.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 17.32 billion, increased by 1.37% YoY

Tag： U-PRESID CHINA 00220.HK profit growth

17:54

【CSPC PHARMA(01093.HK): Receives USD10‑Million Milestone Payment from AstraZeneca】NewTimeSpace News: CSPC Pharma (01093.HK) announced that the Group has received a USD10‑million milestone payment from AstraZeneca for exercising the licensing option of one PCC project under the strategic R&D cooperation agreement on 5 August 2026, signalling steady progress of relevant R&D work as scheduled.

Tag： CSPC PHARMA 01093.HK AstraZeneca strategic cooperation